The findings, reported in November’s Nature Cell Biology, provide new insights into the developmental decisions that are made after fertilisation, to ensure that cells either become committed to forming the placenta or the embryo.
Epigenetic control mechanisms are at the heart of this, orchestrating the formation of many different tissues and organs from a fertilised egg, and ensuring that once certain developmental decisions are made, cell fate is normally irreversible. The discovery of the ability to reverse cell fate through epigenetic regulation of Elf5 offers new insights into regenerative medicine and stem cell therapy.
Cell differentiation is usually a one-way process, starting from a precursor cell that initially has the potential to follow various differentiation pathways, getting increasingly specialised in function until its ‘cell fate’ is realised and it becomes a particular cell type, such as a nerve or muscle cell, a process called terminal differentiation.
The fertilised embryo possesses the greatest plasticity; it is totipotent and can differentiate into all cell types of the foetus as well as the placenta. One of the first definitive divergences in cell differentiation pathways is the point where cells that will form the placenta are set aside from those that will form the foetus. Once this decision has been made, it was thought that there is no turning back or crossover between future placental and embryonic cells. How this strict lineage separation is achieved, however, has remained elusive.
Since all cells in an individual contain the same genetic material, but behave differently depending on which organs eventually comprise, an elaborate mechanism has evolved to fine tune our genes and their expression in different places at different times, leading to the amazing complexity we see in humans despite the relatively small number of unique genes. This process involves specific chemical modifications to the DNA, such as methylation, which modify the structure of the DNA but not its sequence, and regulate gene function. A failure of these epigenetic control mechanisms is linked to a number of human genetic diseases, psychiatric disorders and ageing as well as contributing to some pregnancy complications such as pre-eclampsia. Babraham scientists recently reported that these epigenetic mechanisms can be traced to the divergence of placental mammals and marsupials from the curious egg-laying monotremes, notably the platypus, 150 million years ago.
These ‘epigenetic marks’ are able to impose, and lock in, future cell fate in either placental cell populations or those that embark upon embryonic development. This paper reports on the identification of such an epigenetic restriction of cell lineage fate, directed on a particular gene to keep placental and embryonic cells apart. Elf5 has been identified as the key gene determining cell fate at the gateway of placental versus embryo development.
“The DNA sequence of the gene Elf5 is modified by a methylation mark in future populations of embryonic cells ensuring that the gene is kept in a stable ‘off’ state. In contrast the sequence is not modified in placental cells; the gene is ‘on’ and reinforces placental cell fate. We demonstrated that by removing the methylation mark in embryonic cells, we could convert these normally committed embryonic cells into cells with placental characteristics”, said Dr Myriam Hemberger.
"This is really the first molecular example of an epigenetic restriction of lineage fate. Elf5 really sits at the junction of lineage divergence between the embryonic and trophoblast lineages in early development."
This work has provided new insights into the apparent irreversibility of cell fate and how cell fate is normally locked in to achieve stable differentiation. This is of particular importance for strategies in regenerative medicine that aim to generate a specific cell type from multi- or pluripotent stem cells and to prevent its de-differentiation, a process that bears the risk of tumour formation. Ultimately, these results may pave the way for differentiated cells to be specifically instructed to generate other essential cell types for therapeutic use. This knowledge will open up new possibilities into research of pregnancy complications that have a specific placental origin.
This work was supported by an MRC Career Development fellowship to Dr Hemberger, a Croucher Foundation Fellowship to Dr Ng, by BBSRC, MRC, EU NoE The Epigenome, CellCentric, and DIUS.
Biophysicists reveal how optogenetic tool works
29.05.2020 | Moscow Institute of Physics and Technology
Mapping immune cells in brain tumors
29.05.2020 | University of Zurich
In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".
Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...
Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.
researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...
Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.
When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...
Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.
Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...
Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.
A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
29.05.2020 | Materials Sciences
29.05.2020 | Materials Sciences
29.05.2020 | Power and Electrical Engineering